This article is for informational purposes only and does not constitute medical advice. It reports what FDA labels say. It cannot tell you whether a medication is right for you, and it is not a guide to obtaining a prescription. Always consult your doctor or pharmacist before making any changes to your medication routine.
The number most people quote, BMI 30 or 27 with a weight-related condition, does not appear in the Wegovy indication at all. The label uses the words "obesity" and "overweight" instead. Those numbers come from the clinical trials. For adults, that distinction changes the question you should be asking.
What the label actually says
Here is the Wegovy indications section, quoted in full:
"WEGOVY is indicated in combination with a reduced calorie diet and increased physical activity: - to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. - to reduce excess body weight and maintain weight reduction long term in: - Adults and pediatric patients aged 12 years and older with obesity - Adults with overweight in the presence of at least one weight-related comorbid condition."
Read it twice and notice what is missing. There is no 30. There is no 27. There is no list of qualifying conditions.
The same is true of Zepbound, whose indication also says "adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition."
So where do 30 and 27 come from?
From the trials.
In the Zepbound label, the numbers show up in the Clinical Studies section, describing who was enrolled: "obesity (BMI ≥30 kg/m²), or with overweight (BMI 27 to <30 kg/m²)" for one study, and "adult patients with BMI ≥27 kg/m²" for another.
Wegovy follows the same pattern. Its numeric BMI values appear in Warnings and Precautions, Adverse Reactions, and Clinical Studies, always describing a trial population. They are not in Indications and Usage, and they are not in Dosage and Administration.
That gap matters because trial enrollment criteria and an approved indication are two different things. One describes who was studied. The other describes who the drug is approved to treat. Almost every article on this topic, and Google's own AI summary of it, reports the first as if it were the second.
The word doing the real work is "obesity"
If the indication rests on a word rather than a number, then the definition of that word carries the weight.
That definition moved. In January 2025 a global commission redefined obesity for clinical purposes, splitting it into clinical and preclinical obesity and requiring a waist-based measurement alongside BMI to confirm it. Our companion piece covers what changed and what did not.
This is not a loophole and it does not change any prescription on its own. It is a reason the honest answer to "what BMI do I need" is that BMI alone was never the whole test, and the profession has been moving away from treating it that way.
Same BMI, different doors
Here is the part that gets flattened in most summaries. These medications do not carry identical indications, so the same BMI can open different doors depending on which drug is being discussed.
| Brand | Weight management | Other approved indications | Ages in the label |
|---|---|---|---|
| Wegovy (semaglutide) | Yes | Cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight | Adults and pediatric patients 12 and older |
| Zepbound (tirzepatide) | Yes | Moderate to severe obstructive sleep apnea in adults with obesity | Adults |
| Ozempic (semaglutide) | Not a weight management indication | Type 2 diabetes glycemic control, cardiovascular risk reduction, and kidney outcomes, each in adults with type 2 diabetes | Adults |
Two details in that table are worth pausing on.
Wegovy's cardiovascular indication does not require a weight-related comorbid condition. It requires established cardiovascular disease. That is a different door with a different key.
And Ozempic is the same molecule as Wegovy. Semaglutide in both. But its indications are built entirely around type 2 diabetes, with no BMI condition anywhere. Same drug, different brand, different question.
Zepbound's sleep apnea indication is newer, approved in December 2024, and it is the only one of the three that has it.
Your insurer is running a different rulebook
Label criteria and coverage criteria are not the same document, and the second one is usually stricter.
Insurers set their own prior authorization rules, which can include BMI floors, documented diet attempts, duration requirements, and step therapy through other drugs first. A prescription that fits the FDA label can still be denied by a plan, and the appeal runs on the plan's terms, not the label's.
This is also where BMI is most likely to still be used as a single number. The American Medical Association took a position on exactly that in June 2023, adopting a policy stating BMI "should not be used as a sole criterion to deny appropriate insurance reimbursement." The same policy notes that BMI "loses predictability when applied on the individual level." A policy position is not a binding rule on insurers, which is why the practice persists.
Worth separating clearly: none of this is a reason to expect a denial, and none of it is a reason to expect approval. It is a reason to ask the clinic what your specific plan requires before the paperwork starts, rather than after.
What to actually bring to the appointment
Since the label leans on clinical judgment rather than a threshold, the useful preparation is not a BMI calculation. It is the material a prescriber needs to make that judgment.
Your measured height and weight, taken at the office rather than remembered. A waist measurement, which the 2025 criteria call for. A list of your conditions, since a weight-related condition or established cardiovascular disease can matter as much as the BMI figure. Your current medications. And your insurance plan's specific requirements, which the clinic's staff deal with constantly.
The question that gets you further than "do I qualify" is "which indication would we be treating under, and what does my plan require for it."
Once a prescription starts
If you do end up on one of these, the practical problem changes shape immediately. These are weekly injections, and weekly dosing has a failure mode that daily dosing does not: it is genuinely easy to lose track of which day you took it.
Pillo's alarms keep going until you mark the dose taken, which is what separates a snoozed notification from a dose you actually gave yourself. Weekly schedules sit alongside daily ones, so a Wednesday injection and a morning tablet do not compete for the same mental slot.
Once you are started, the questions shift to timing and recovery, like what to do about a missed Wegovy dose, what happens if you accidentally take two, and whether you can move your injection day. If tablets rather than injections are on the table, oral GLP-1 options differ in how they fit a routine, and switching between brands has its own tradeoffs. The weekly dose anxiety that comes with all of this is common enough to have been written about. And if surgery rather than medication is the route taken, absorption changes for other prescriptions too, as it does with thyroid medication after a gastric bypass.
FAQ
What BMI do you need for Wegovy?
The Wegovy indication does not state a BMI number. It describes adults and pediatric patients 12 and older with obesity, adults with overweight plus at least one weight-related comorbid condition, and adults with established cardiovascular disease and obesity or overweight. The commonly quoted 30 and 27 figures come from the clinical trial populations, not the indication.
What disqualifies you from taking Wegovy?
Contraindications are listed in the label rather than being a BMI question. For tirzepatide products such as Zepbound, the label contraindicates use in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. Your prescriber reviews the full contraindication and warning list against your history.
Can I get Ozempic if my BMI is 31?
Ozempic is not approved as a weight management medication. Its indications are built around type 2 diabetes, so BMI is not the criterion being applied. Wegovy contains the same active ingredient and carries the weight management indications instead.
Is the BMI cutoff different for Zepbound and Wegovy?
Neither indication states a numeric cutoff, so there is no published cutoff to compare. What genuinely differs is the additional indications each carries. Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity, and Wegovy is approved for cardiovascular risk reduction and for patients as young as 12.
Does insurance use the same BMI rule as the label?
Usually not. Insurers apply their own prior authorization criteria, which are frequently stricter than the label and can include specific BMI floors, documented prior attempts, and step therapy. Meeting the label is not the same as meeting your plan.
Why do so many sources say BMI 30 or 27?
Because those were the enrollment criteria for the clinical trials, and trial criteria are easy to mistake for approval criteria. They are a reasonable shorthand for the population studied. They are not the text of the indication.
This article is for informational purposes only and does not constitute medical advice. Always consult your doctor or pharmacist before making any changes to your medication routine. Consult your doctor or pharmacist for advice specific to your medications.
